



**VIRUPAKSHA™**

**Date: 11-12-2025**

To,

The Manager  
BSE Limited  
P. J. Towers, Dalal Street  
Mumbai-400001  
(BSE Scrip Code: 524636)

Dear Sir/ Madam,

**Sub: Intimation under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ('SEBI Listing Regulations') to Stock Exchanges regarding approval of the shareholders for Reclassification of person(s) forming part of the Promoter/ Promoter Group from "Promoter/ Promoter Group Category" to "Public Category" shareholder(s) Regulation 31A of the SEBI Listing Regulations.**

Dear Sir/ Madam,

In terms of Regulation 30 read with Regulation 31A of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we would like to inform you that shareholders of the Company in the Postal Ballot held between 12<sup>th</sup> November, 2025 from 09:00 a.m. to 11<sup>th</sup> December, 2025 from 05:00 p.m., have approved Reclassification of person(s) forming part of the Promoter/ Promoter Group from "Promoter/ Promoter Group Category" to "Public Category" shareholder (as mentioned in the notice and results) of the Company with requisite majority.

The person(s) as detailed in the **Annexure – I** below forming a part of Promoter/ Promoter Group are now reclassified as "Public" Category Shareholder(s) with immediate effect and will not be reported as part of the Promoter Group Shareholders in the shareholding pattern that will be filed with the Stock Exchanges under Regulation 31 of the SEBI Listing Regulations, going forward.

Certified true copy of the resolution passed by the shareholders of the Company via Postal Ballot and NOC letter of BSE along with voting results respectively are enclosed herewith for reference.

This is for your information and records.

Thanking You,  
**For Oxygenta Pharmaceutical Limited**

**Balasubba Reddy Mamilla**  
**Whole-time Director**  
**DIN: 01998852**

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: [info@oxygentapharma.com](mailto:info@oxygentapharma.com). Website: [www.oxygentapharma.com](http://www.oxygentapharma.com),

Phone 040-23073417, CIN: L24110TG1990PLC012038

**Annexure -I**

**List of Applicants whose re-classification of shareholding from “Promoter/ Promoter group” category to “Public” category has been approved by the shareholders:**

<b>Name of the Shareholder</b>	<b>Category</b>	<b>No. of Shares held</b>	<b>% of Paid-up Capital</b>
Mr. Sai Sudhakar Vankineni	Promoter	30,000	0.08
Ms. Snigdha Vankineni	Promoter	5,43,000	1.47
Mr. Sumanth Simha Vankineni	Promoter	3,43,700	0.93
Mr. Mrs. Jhansi Rani Vankineni	Promoter	26,000	0.0

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: [info@oxygentapharma.com](mailto:info@oxygentapharma.com). Website: [www.oxygentapharma.com](http://www.oxygentapharma.com),

Phone 040-23073417, CIN: L24110TG1990PLC012038



**EXTRACTS OF THE RESOLUTION PASSED BY THE SHAREHOLDERS OF OXYGENTA PHARMACEUTICAL LIMITED ("COMPANY") THROUGH POSTAL BALLOT HELD BETWEEN WEDNESDAY, NOVEMBER 12, 2025 TO THURSDAY, DECEMBER 11, 2025.**

**SUB: RECLASSIFICATION OF PERSON(S) FORMING PART OF THE PROMOTER/ PROMOTER GROUP FROM "PROMOTER/ PROMOTER GROUP CATEGORY" TO "PUBLIC CATEGORY" SHAREHOLDER OF THE COMPANY.**

**"RESOLVED THAT** pursuant to applicable provisions of Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI (LODR) Regulations, 2015') (including any statutory modification(s) or re-enactment thereof, for the time being in force) and in accordance with the No Objection received from BSE Limited vide letter No./Ref No. LIST/COMP/KR/514/2025-26 dated October 16, 2025 respectively, and subject to necessary approvals from such statutory authorities as may be necessary, the consent of the Members of the Company be and is hereby accorded for reclassification the following persons forming part of Promoter/ Promoter Group Shareholder (hereinafter referred to as the ("Outgoing Promoter(s)/ Promoter Group" Shareholder(s)) from "Promoter(s)/ Promoter Group" Shareholder(s) to "Public" Shareholder:

Name of the Shareholder	Category	No. of Shares held	% of Paid-up Capital
Mr. Sai Sudhakar Vankineni	Promoter	30,000	0.08
Ms. Snigdha Vankineni	Promoter	5,43,000	1.47
Mr. Sumanth Simha Vankineni	Promoter	3,43,700	0.93
Mr. Mrs. Jhansi Rani Vankineni	Promoter	26,000	0.0

**"RESOLVED FURTHER THAT** pursuant to provisions of Regulation 31A of SEBI (LODR) Regulations, 2015, the above-named Outgoing Promoter(s)/Promoter Group Shareholder(s) have confirmed that they shall not:

- hold more than 10% of the fully paid-up equity share capital and voting rights of the Company.;
- exercise control over the affairs of the Company, directly or indirectly;
- have any special rights through formal or informal arrangements, including through any shareholder
- agreements, if any, granting special rights to them shall be terminated;
- be represented on the Board of Directors (including not having a nominee director) of the Company;
- act as a Key Managerial Personnel in the Company;

and shall at all times from the date of such reclassification, continue to comply with conditions mentioned under sub regulation (4) of Regulation 31A of SEBI (LODR) Regulations, 2015, post reclassification from "Promoter/Promoter Group" Shareholder(s) to "Public" Shareholder."

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone 040-23073417, CIN: L24110TG1990PLC012038



**“RESOLVED FURTHER THAT** as required under the provisions of Regulation 31A of SEBI (LODR) Regulations, 2015, the above-mentioned Outgoing Promoter(s)/ Promoter Group Shareholder(s) have further confirmed that they are neither a ‘wilful defaulter’ as per the Reserve Bank of India Guidelines nor a fugitive economic offender.”

**“RESOLVED FURTHER THAT** any Director or the Company Secretary of the Company be and are hereby severally authorized to do all such acts, deeds, matters and things as may be considered necessary, desirable or expedient in this regard as per the applicable laws and make all necessary filings and to execute all such deeds, documents or writings as are necessary or expedient, to settle any questions, difficulties or doubt that may arise in this behalf and to represent before such authorities as may be required and to do and perform all such acts, deeds and things as may be required to give effect to the above resolution.”

The resolution was passed with requisite majority.

**//CERTIFIED TRUE COPY//**

**For Oxygenta Pharmaceutical Limited**

**Balasubba Reddy Mamilla**  
**Whole-time director**  
**DIN: 01998852**

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080  
Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: [info@oxygentapharma.com](mailto:info@oxygentapharma.com). Website: [www.oxygentapharma.com](http://www.oxygentapharma.com),

Phone 040-23073417, CIN: L24110TG1990PLC012038





**EXPLANATORY STATEMENT**  
**[PURSUANT TO SECTION 102(1) AND 110 OF THE COMPANIES ACT, 2013]**

**ITEM NO. 1: Reclassification of person(s) forming part of the Promoter/ Promoter Group from “Promoter/ Promoter Group Category” to “Public Category” shareholder of the Company.**

As required by Section 102 of the Companies Act, 2013, the following Statement sets out all material facts relating to the Special Business (Item No.1) mentioned in the Notice of Postal Ballot: Item No.1: Regulation 31A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI (LODR) Regulations, 2015”), has provided a regulatory mechanism for reclassification of Promoter or Promoter Group Shareholder to ‘Public’ Shareholder.

The Board of Directors had received an application(s) dated August 19, 2025 from Mr. Sai Sudhakar Vankineni, Ms. Snigdha Vankineni, Mr. Sumanth Simha Vankineni and Mrs. Jhansi Rani Vankineni (“Outgoing Promoter(s)/Promoter Group” Shareholder(s)) forming part of Promoter Shareholder holding shares aggregating to 9,42,700 (Nine Lakhs Forty-Two Thousand Seven Hundred Only) (Pre shareholding) (2.55%) equity shares to re-classify themselves as Public Shareholder(s).

The Board of Directors vide resolution passed at the meeting dated August 25, 2025 took note of above application(s) and granted their consent to proceed with the process of reclassification of status of Mr. Sai Sudhakar Vankineni, Ms. Snigdha Vankineni, Mr. Sumanth Simha Vankineni and Mrs. Jhansi Rani Vankineni (“Outgoing Promoter(s)/Promoter Group” Shareholder(s)) from “Promoter(s)/ Promoter Group” Shareholder(s) to “Public” Shareholder(s) subject to necessary approvals from the stock exchanges where the shares of the Company are listed and further subject to approval of shareholders of the Company and other appropriate statutory authorities, as may be necessary.

A certified true copy of the resolution passed by the Board of Directors at their meeting held on August 25, 2025, is enclosed as **Annexure I**.

Accordingly, in response to the Company’s application to the Stock Exchanges on August 29, 2025, the Company received No Objection from the BSE Limited (BSE) vide letter bearing Ref. No. LIST/COMP/KR/514/2025-26 dated October 16, 2025 respectively for reclassification of Mr. Sai Sudhakar Vankineni, Ms. Snigdha Vankineni, Mr. Sumanth Simha Vankineni and Mrs. Jhansi Rani Vankineni (“Outgoing Promoter(s)/Promoter Group” Shareholder(s)) from “Promoter(s)/ Promoter Group” Shareholder(s) to “Public” Shareholder(s). Copy of No-objection as received from BSE is enclosed as **Annexure II**.

**Details of Outgoing Promoter(s)/ Promoter Group Shareholder(s) are as follows:**

<b>Name of the Shareholder</b>	<b>Category</b>	<b>No. of Shares held</b>	<b>% of Paid-up Capital</b>
Mr. Sai Sudhakar Vankineni	Promoter	30,000	0.08
Ms. Snigdha Vankineni	Promoter	5,43,000	1.47
Mr. Sumanth Simha Vankineni	Promoter	3,43,700	0.93
Mrs. Jhansi Rani Vankineni	Promoter	26,000	0.07

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone 040-23073417, CIN: L24110TG1990PLC012038



Vide the aforesaid application(s) of Mr. Sai Sudhakar Vankineni, Ms. Snigdha Vankineni, Mr. Sumanth Simha Vankineni and Mrs. Jhansi Rani Vankineni ("Outgoing Promoter(s)/Promoter Group" Shareholder(s)), they had individually confirmed that they:

- a. Do not hold more than 10% of the fully paid-up equity share capital and voting rights of the Company;
- b. Do not exercise control over the affairs of the listed entity directly or indirectly;
- c. Do not have any special rights through formal or informal agreements and shareholding agreements, if any, granting special rights to them shall be terminated;
- d. Do not represented on the Board of Directors (including as a nominee director) of the Company; and
- e. Do not act as a Key Managerial Personnel in the Company;

and shall at all times from the date of such reclassification, continue to comply with conditions mentioned under Regulation 31A of SEBI (LODR) Regulations, 2015, post reclassification from "Promoter" Shareholder to "Public" Shareholder.

Further, the Outgoing Promoter(s)/ Promoter Group Shareholder(s) have confirmed in their individual capacity that they are neither a 'wilful defaulter' as per the Reserve Bank of India Guidelines nor a fugitive economic offender.

Further, the Board confirms that the Company post this reclassification:

- a. will be compliant with the requirement for minimum public shareholding as required under Regulation 38 of SEBI (LODR) Regulations, 2015;
- b. Trading in the Company's shares has not been suspended by stock exchanges and
- c. The Company does not have any outstanding dues to the Securities and Exchange Board of India, the stock exchanges or depositories.

The Board recommends the resolution set out at Item No. 1 of the Notice for approval by the Members by way of an Ordinary Resolution.

None of the Directors or Key Managerial Personnel of the Company or their relatives are interested or concerned, financially or otherwise, in the resolution.

**//CERTIFIED TRUE COPY//**

**For Oxygenta Pharmaceutical Limited**

**Balasubba Reddy Mamilla**  
**Whole-time director**  
**DIN: 01998852**

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off.& Factory: Sy.No. 252/1, Aroor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone 040-23073417, CIN: L24110TG1990PLC012038





**EXTRACTS OF THE RESOLUTION PASSED AT THE MEETING OF THE BOARD OF DIRECTORS OF M/S. OXYGENTA PHARMACEUTICAL LIMITED ('THE COMPANY') HELD ON MONDAY, 25<sup>TH</sup> AUGUST, 2025 AT 05:00 P.M. IST AT THE REGISTERED OFFICE OF THE COMPANY SITUATED AT SURVEY NO 252/1, AROOR VILLAGE, SADASIVAPET MANDAL, MEDAK - 502291, TELANGANA, INDIA.**

**SUB: APPLICATION RECEIVED FROM SHAREHOLDER(S) FOR RECLASSIFICATION OF THEIR STATUS FROM "PROMOTER GROUP" SHAREHOLDER TO "PUBLIC" SHAREHOLDER:**

**"RESOLVED THAT** the Board of Directors hereby takes on record the Request Letter dated 19<sup>th</sup> August, 2025 received from shareholders as detailed below ("Outgoing Promoter Group Shareholder") forming part of 'Promoter and Promoter Group' of the Company for reclassification their status from "Promoter Group Shareholder" to "Public Shareholder", copy of which is placed before this meeting."

**Details of Outgoing Promoters as below:**

S N o.	Name of Outgoing Promoter	Requesting change in Category	Date of receipt of Application	Number of Equity Shares held as on the date of the Application	Percentage of Equity Shares held on the date of the Application
1.	Sai Sudhakar Vankineni	Promoter to Public	19.08.2025	30,000	0.08
2.	Snigdha Vankineni	Promoter to Public	19.08.2025	5,43,000	1.47
3.	Sumanthi Simha Vankineni	Promoter to Public	19.08.2025	3,43,700	0.93
4.	Jhansi Rani Vankineni	Promoter to Public	19.08.2025	26,000	0.07

**"RESOLVED FURTHER THAT** pursuant to Regulation 31A(3)(a)(ii) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended from time to time ("SEBI LODR Regulations"), including any statutory modification(s) or reenactment thereof, for the time being in force, and subject to necessary approvals from the stock exchanges where the shares of the Company are listed and subject to approval of shareholders of the Company and other applicable statutory authorities, as may be necessary, the consent of the Board of Directors be and is hereby accorded to proceed with the process of reclassification of status of the Promoters mentioned above ("Outgoing Promoter Group Shareholder") from "Promoter Group Shareholder" to "Public Shareholder" as per the request letter sent by the shareholder."

**"RESOLVED FURTHER THAT** the Board of Directors hereby takes note that as required under the provisions of Regulation 31(A)(3)(b) of SEBI LODR Regulations, the Outgoing Promoter(s) Shareholder(s) has confirmed that they shall not:

- hold more than 10% of the fully paid-up equity share capital and voting capital of the Company;
- exercise control over the affairs of the listed entity directly or indirectly;

**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Arcor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad - 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone: 040-23073417. CIN: L24110TG1990PLC012038



- c) have any special rights through formal or informal agreements and shareholding agreements, if any, granting special rights to him shall be terminated;
- d) be represented on the Board of Directors (including as a nominee director) of the Company;
- e) act as a key managerial personnel in the Company;

and shall at all times from the date of such reclassification, continue to comply with conditions mentioned Regulation 31A of SEBI (LODR) Regulations, 2015 post reclassification from "Promoter & Promoter Group" to "Public".

**"RESOLVED FURTHER THAT** the Board of Directors hereby takes note that as required under the provisions of Regulation 31(A)(3)(b) of SEBI LODR Regulations, the abovementioned the Outgoing Promoter Group Shareholder(s) has further confirmed in their individual capacity that they are neither a 'willful defaulter' as per the Reserve Bank of India Guidelines nor a fugitive economic offender."

**"RESOLVED FURTHER THAT** pursuant to provisions of 31A(3)(c) of SEBI LODR Regulations, the Board of Directors hereby confirms that:

- (i) the Company is and post reclassification will be compliant with the requirement for minimum public shareholding as required under Regulation 38 of SEBI LODR Regulations;
- (ii) Trading in Company's shares has not been suspended by stock exchanges;
- (iii) The Company does not have any outstanding dues to the Securities and Exchange Board of India, the stock exchanges or depositories."

**"RESOLVED FURTHER THAT** the Directors or the Chief Financial Officer or the Company Secretary of the Company be and are hereby authorized, severally and or jointly, as the case may be, to do all such things and take all such steps and actions including signing certified true copy of the resolution, making of application(s), furnishing of affidavit(s), declaration(s), indemnities, document(s) etc. on behalf of the Company that may be required to be submitted to stock exchanges/any other regulatory authority and to complete all requisite formalities as may be necessary in this regard."

//CERTIFIED TRUE COPY//

FOR OXYGENTA PHARMACEUTICAL LIMITED

**BALASUBBA REDDY MAMILLA**  
EXECUTIVE DIRECTOR  
(DIN: 01998852)



**OXYGENTA PHARMACEUTICAL LIMITED** (Subsidiary of **VIRUPAKSHA ORGANICS LIMITED**)

(An ISO 9001:2015, ISO 14001:2018 and ISO 45001:2015 Certified Company)

Regd off. & Factory: Sy.No. 252/1, Arcor (V), Sadasivapet (M), Sangareddy (Dist)-502 291, Telangana, INDIA. Tel: 08455-250080

Corp. Office: Level-1, Plot No. B1 & B2, IDA Gandhi Nagar, Kukatpally, Hyderabad – 500 037, Telangana, INDIA.

E-Mail id: info@oxygentapharma.com. Website: www.oxygentapharma.com,

Phone: 040-23073417. CIN: L24110TG1990PLC012038



LIST/COMP/KR/514/2025-26

October 16, 2025

The Company Secretary/ Compliance Officer

**Oxygenta Pharmaceutical Ltd.**

Survey No 252/1,

Aroor (V), Sadasivapet (M),

Sangareddy (District), Telangana - 502291

**Subject: No-objection for reclassification of Promoter(s) under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015**

Dear Sir / Madam,

This is in reference to your application dated, August 29, 2025, requesting no-objection for the reclassification of promoter(s) under Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


Based on the submission made by the Listed Entity, the Exchange grants no-objection for the reclassification request dated, August 29, 2025, for the following promoter(s) in accordance with Regulation 31A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Sr. No.	Name of Promoter(s) / Promoter(s) Group
1.	SAI SUDHAKAR VANKINENI
2.	SNIGDHA VANKINENI
3.	SUMANTH SIMHA VANKINENI
4.	JHANSI RANI VANKINENI

You are required to ensure compliance with subsequent relevant disclosures of material events related to this reclassification, in accordance with the applicable provisions of Regulation 31A of SEBI (LODR) Regulations, 2015.

Yours faithfully,

  
**Shyam Bhagirath**  
Manager  
Listing Compliance

  
**Krishna Rathi**  
Deputy Manager  
Listing Compliance

Reclassification of Promoters: Oxygenta Pharmaceutical Ltd.